Prognostic value of pre-and posttreatment PET/CT parameters in patients diagnosed with advanced stage NSCLC

Background: PET imaging involves several parameters. However, it is not well known which parameters in each measurable site of tumors may have a greater effect on oncologic outcomes. Method: This study included a total of 42 patients diagnosed with histology-proven NSCLC. Baseline and consecutive FDG-PET scans were carried out 3 weeks before and at least 3 months after treatment, respectively. Results: According to the PERCIST, 9 (21%) patients had Complete Response (CR), and 3 of them underwent surgical resection. Sixteen patients (38%) had Partial Response (PR), and 4 (9.5%) had Stable Disease (SD), the remaining 15 (35%) had Progressive Disease (PD). Patients who responded to the treatment had significantly higher Overall Survival (OS) and Progression Free Survival (PFS), 15 versus 9.5 months and 10 versus 6 months, respectively. The SUVmax values decreased from 12.2 to 3.7 (P=<0.001), and the mediastinal lymph nodes SUVmax decreased from 6 to 0 (P=<0.001) in the responder group. The median TLG of the primary lesion showed a statistically significant decrease from 279 to 13.6 (P=0.0001), the median TLG of the mediastinal lymph nodes decreased from 13.2 to 0 (P= 0.04), and the median Whole Body (WB) TLG decreased from 338 to 17 (P=0.002) in the responder group. The posttreatment WB TLG was significantly correlated with OS and PFS. Conclusion: This study showed that the posttreatment WB TLG is significantly associated with oncologic outcomes. The metabolic changes in the mediastinal lymph nodes, as shown by the SUVmax and TLG, have a prognostic value in patients who develop new metastases during treatment. Further study in a homogenous NSCLC population can help increase our understanding of the prognostic value of PET/CT parameters. © 2018 Bentham Science Publishers.

Yazar Bilir C.
Yusufoglu B.
Kızılkaya B.
Engin H.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/7206
Tek Biçim Adres 10.2174/1573405613666170322155601
Konu Başlıkları Histology-proven NSCLC
Lung cancer
PET/CT
Survival
SUV
Total lesion glycolysis
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
Dergi Adı Current Medical Imaging Reviews
Dergi Cilt Bilgisi 14
Dergi Sayısı 4
Sayfalar 621 - 628
Yayın Yılı 2018
Eser Adı
[dc.title]
Prognostic value of pre-and posttreatment PET/CT parameters in patients diagnosed with advanced stage NSCLC
Yazar
[dc.contributor.author]
Bilir C.
Yazar
[dc.contributor.author]
Yusufoglu B.
Yazar
[dc.contributor.author]
Kızılkaya B.
Yazar
[dc.contributor.author]
Engin H.
Yayın Yılı
[dc.date.issued]
2018
Yayıncı
[dc.publisher]
Bentham Science Publishers B.V.
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background: PET imaging involves several parameters. However, it is not well known which parameters in each measurable site of tumors may have a greater effect on oncologic outcomes. Method: This study included a total of 42 patients diagnosed with histology-proven NSCLC. Baseline and consecutive FDG-PET scans were carried out 3 weeks before and at least 3 months after treatment, respectively. Results: According to the PERCIST, 9 (21%) patients had Complete Response (CR), and 3 of them underwent surgical resection. Sixteen patients (38%) had Partial Response (PR), and 4 (9.5%) had Stable Disease (SD), the remaining 15 (35%) had Progressive Disease (PD). Patients who responded to the treatment had significantly higher Overall Survival (OS) and Progression Free Survival (PFS), 15 versus 9.5 months and 10 versus 6 months, respectively. The SUVmax values decreased from 12.2 to 3.7 (P=<0.001), and the mediastinal lymph nodes SUVmax decreased from 6 to 0 (P=<0.001) in the responder group. The median TLG of the primary lesion showed a statistically significant decrease from 279 to 13.6 (P=0.0001), the median TLG of the mediastinal lymph nodes decreased from 13.2 to 0 (P= 0.04), and the median Whole Body (WB) TLG decreased from 338 to 17 (P=0.002) in the responder group. The posttreatment WB TLG was significantly correlated with OS and PFS. Conclusion: This study showed that the posttreatment WB TLG is significantly associated with oncologic outcomes. The metabolic changes in the mediastinal lymph nodes, as shown by the SUVmax and TLG, have a prognostic value in patients who develop new metastases during treatment. Further study in a homogenous NSCLC population can help increase our understanding of the prognostic value of PET/CT parameters. © 2018 Bentham Science Publishers.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Histology-proven NSCLC
Konu Başlıkları
[dc.subject]
Lung cancer
Konu Başlıkları
[dc.subject]
PET/CT
Konu Başlıkları
[dc.subject]
Survival
Konu Başlıkları
[dc.subject]
SUV
Konu Başlıkları
[dc.subject]
Total lesion glycolysis
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1573-4056
İlk Sayfa Sayısı
[dc.identifier.startpage]
621
Son Sayfa Sayısı
[dc.identifier.endpage]
628
Dergi Adı
[dc.relation.journal]
Current Medical Imaging Reviews
Dergi Sayısı
[dc.identifier.issue]
4
Dergi Cilt Bilgisi
[dc.identifier.volume]
14
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.2174/1573405613666170322155601
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/7206
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
9
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
17 Şubat 2024 00:27
Google Kontrol
Tıklayınız
patients decreased median parameters SUVmax months treatment mediastinal significantly respectively Survival posttreatment showed versus Disease oncologic outcomes prognostic Response responder decrease significant statistically lesion primary values Background increase during Further homogenous population understanding PET/CT Bentham
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms